@article {Okada49, author = {Okada, Yasunobu and Okada, Toshiaki and Sato-Numata, Kaori and Islam, Md. Rafiqul and Ando-Akatsuka, Yuhko and Numata, Tomohiro and Kubo, Machiko and Shimizu, Takahiro and Kurbannazarova, Ranohon S. and Marunaka, Yoshinori and Sabirov, Ravshan Z.}, editor = {Ishikawa, Yoshihiro}, title = {Cell Volume-Activated and Volume-Correlated Anion Channels in Mammalian Cells: Their Biophysical, Molecular, and Pharmacological Properties}, volume = {71}, number = {1}, pages = {49--88}, year = {2019}, doi = {10.1124/pr.118.015917}, publisher = {American Society for Pharmacology }, abstract = {There are a number of mammalian anion channel types associated with cell volume changes. These channel types are classified into two groups: volume-activated anion channels (VAACs) and volume-correlated anion channels (VCACs). VAACs can be directly activated by cell swelling and include the volume-sensitive outwardly rectifying anion channel (VSOR), which is also called the volume-regulated anion channel; the maxi-anion channel (MAC or Maxi-Cl); and the voltage-gated anion channel, chloride channel (ClC)-2. VCACs can be facultatively implicated in, although not directly activated by, cell volume changes and include the cAMP-activated cystic fibrosis transmembrane conductance regulator (CFTR) anion channel, the Ca2+-activated Cl- channel (CaCC), and the acid-sensitive (or acid-stimulated) outwardly rectifying anion channel. This article describes the phenotypical properties and activation mechanisms of both groups of anion channels, including accumulating pieces of information on the basis of recent molecular understanding. To that end, this review also highlights the molecular identities of both anion channel groups; in addition to the molecular identities of ClC-2 and CFTR, those of CaCC, VSOR, and Maxi-Cl were recently identified by applying genome-wide approaches. In the last section of this review, the most up-to-date information on the pharmacological properties of both anion channel groups, especially their half-maximal inhibitory concentrations (IC50 values) and voltage-dependent blocking, is summarized particularly from the standpoint of pharmacological distinctions among them. Future physiologic and pharmacological studies are definitely warranted for therapeutic targeting of dysfunction of VAACs and VCACs.}, issn = {0031-6997}, URL = {http://stonel.info/content/71/1/49}, eprint = {http://stonel.info/content/71/1/49.full}, journal = {Pharmacological Reviews} }